DrugPipeline.net has announced the addition of “World Intravenous (IV) Ibuprofen Market - Opportunities and Forecasts, 2015 - 2022” research report to their website DrugPipeline.net

Bangalore, India -- (SBWire) -- 06/02/2016 --Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The intravenous (IV) route for ibuprofen administration has a faster onset of action as compared to the other routes. IV ibuprofen is preferred for the management of post-operative and acute pain. The demand for ibuprofen has increased due to the side effects of opioid analgesics such as respiratory depression, allergic reactions, sedation, and gastrointestinal events.

The market for IV ibuprofen for pain management is in its nascent stage. The world IV ibuprofen market was valued at $3.6 million in 2015, and is projected to reach $14.2 million by 2022, registering a CAGR of 20% during the forecast period. Advantages associated with IV ibuprofen such as rapid result and targeted drug delivery have resulted in the growth of this market. In 2015, FDA approved IV ibuprofen for pediatric use, due to which the market is expected to register a significant growth during the forecast period. Other factors that affect the market growth significantly include increasing incidence of cancer, cardiovascular ailments, pain, headache, toothache, back pain, arthritis, trauma, and shifting trend towards the use of non-opioids drugs. Factors that would hamper the market growth include side effects associated with IV ibuprofen and lengthy approval process.

The world IV Ibuprofen market is segmented on the basis of indication, age group, and country. By indication, further sub-segments considered in this report include pain/inflammation and fever. The age groups considered are pediatrics and adults. The market is segmented into four countries namely Australia, Canada, South Korea, and the U.S.

Currently, Cumberland Pharmaceuticals Inc., is the only IV ibuprofen manufacturer in the market. The company has collaborated with the local/regional drug manufacturers to target new countries by getting product approvals. The key companies profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc. (acquired by Teligent, Inc.), CSL Limited, Sandor Medicaids Pvt Ltd., PT. Soho Industri Pharmasi, Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., and Laboratorios Valmorca, C.A.

Spanning over 65 pages "World Intravenous (IV) Ibuprofen Market - Opportunities and Forecasts, 2015 - 2022" report covers Introduction, Executive Summary, Market Overview, World Analgesics Market, By Age Group, 2015-2022, World Analgesics Market, By Indication, 2015-2022, World Analgesics Market, By Country, 2015-2022, Company Profiles.

For more information Visit at: http://www.drugpipeline.net/allied-market-research/world-intravenous-iv-ibuprofen-market-opportunities-and-forecasts-2015-2022

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.